Icagen 10-Q 15 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	15-May-15
Document and Entity Information [Abstract]
Entity Registrant Name	XRpro Sciences, Inc.
Entity Central Index Key	1518520
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		6,373,707

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015		Dec. 31, 2014
Current assets:
Cash	$8,984,011		$6,472,393
Accounts receivable, net	30,651		103,869
Prepaid expenses	34,838		55,331
Total current assets	9,049,500		6,631,593
Non-current assets:
Intangible assets, net	478,286		491,207
Plant and equipment, net	500,574		481,651
Deposits	1,000		1,000
Investment in certificate of deposit	25,014		25,014
Total non-current assets	1,004,874		998,872
TOTAL ASSETS	10,054,374		7,630,465
Current liabilities:
Accounts payable	713,005		556,099
Other payables and accrued expenses	805,098		785,253
Loans payable	34,985		34,552
Dividends payable	11,987		978,048
Total current liabilities	1,565,075		2,353,952
Non-current liabilities:
Loans payable	133,591		142,502
Total non-current liabilities	133,591		142,502
TOTAL LIABILITIES	1,698,666		2,496,454
Convertible Redeemable Preferred Stock
Series A Cumulative Convertible Redeemable Preferred Stock, $0.001 par value, 400,000 shares designated, 105,000 shares issued and outstanding as of March 31, 2015 and December 31, 2014, liquidation preference is $5.70 per share.	133,350		133,350
Commitments and contingencies
STOCKHOLDERS' EQUITY :
Preferred stock, $0.001 par value, 10,000,000 authorized shares, 6,600,000 shares undesignated and unissued.
Series B Cumulative Convertible Preferred Stock, $0.001 par value, 3,000,000 designated shares, 0 and 2,133,947 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively, liquidation preference is $2.50 per share.			2,134
Common stock, $0.001 par value, 50,000,000 authorized shares, 6,700,707 and 3,780,847 shares issued and 6,373,707 and 3,453,847 outstanding as of March 31, 2015 and December 31, 2014, respectively.*	6,374	[1]	3,453	[1]
Additional paid in capital	23,122,836		18,413,353
Treasury stock, at cost (327,000 shares of common stock as of March 31, 2015 and December 31, 2014).*	-237	[1]	-237	[1]
Accumulated deficit	-14,906,615		-13,418,042
Total stockholders' equity	8,222,358		5,000,661
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$10,054,374		$7,630,465
[1]	After giving retrospective effect to a 2 for 1 reverse stock split which became effective on March 25, 2015 after filing a certificate of amendment to the certificate of incorporation.

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Preferred stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock undesignated and unissued shares	6,600,000	6,600,000
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	6,700,707	3,780,847
Common stock, shares outstanding	6,373,707	3,453,847
Treasury stock, shares	327,000	327,000
Series A Preferred Stock
Convertible redeemable preferred stock, par value	$0.00	$0.00
Convertible redeemable preferred stock, shares designated	400,000	400,000
Convertible redeemable preferred stock, shares issued	105,000	105,000
Convertible redeemable preferred stock, shares outstanding	105,000	105,000
Convertible redeemable preferred stock, liquidation preference per share	$5.70	$5.70
Series B Preferred Stock [Member]
Convertible redeemable preferred stock, par value	$0.00	$0.00
Convertible redeemable preferred stock, shares designated	3,000,000	3,000,000
Convertible redeemable preferred stock, shares issued	0	2,133,947
Convertible redeemable preferred stock, shares outstanding	0	2,133,947
Convertible redeemable preferred stock, liquidation preference per share	$0	$2.50

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Statements of Operations [Abstract]
Sales	$30,653		$254,220
Cost of sales	162,201		176,972
Gross (loss) profit	-131,548		77,248
Operating expenses:
Selling, general and administrative expenses	1,251,074		1,233,961
Depreciation	32,226		26,959
Amortization	12,921		12,920
Total operating expenses	1,296,221		1,273,840
Operating loss	-1,427,769		-1,196,592
Other (expense) income
Other income	161		7,177,522
Interest income	1,854		36
Interest expense	-2,164		-6,567
Change in fair value of derivative financial liabilities			-553,420
Total other (expense) income	-149		6,617,571
Net (loss) income	-1,427,918		5,420,979
Preferred stock dividends	-60,655		-149,993
Net (loss) income applicable to common stock	($1,488,573)		$5,270,986
Net (loss) income per common share: -
Basic	($0.26)		$2.54
Diluted	($0.26)		$1.68
Weighted average number of common stock outstanding: -
Basic	5,653,144	[1]	2,076,760	[1]
Diluted	5,653,144	[1]	3,231,030	[1]
[1]	After giving retrospective effect to a 2 for 1 reverse stock split which became effective on March 25, 2015 after filing a certificate of amendment to the certificate of incorporation.

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Cash flow from operating activities
Net (loss) income	($1,427,918)	$5,420,979
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities
Depreciation	32,226	26,959
Amortization	12,921	12,920
(Gain) on disposal/scrapping of plant and equipment	-161	-462
Stock based compensation charge	209,862	186,523
Increase in fair value of derivative financial liability		553,420
Gain on cancellation of shares in legal settlement		-177,522
Changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	73,218	-73,986
Decrease (increase) in prepaid expenses and deposits	20,493	-27,124
Increase (decrease) in accounts payable	156,906	-1,132,863
Increase (decrease) in other payables and accrued expenses	19,834	-18,151
Net cash (used in) provided by operating activities	-902,619	4,770,693
Cash flow from investing activities
Purchase of plant and equipment	-51,923	-20,227
Proceeds from sale of equipment	934	2,750
Investment in deposits		-1,000
Net cash used in investing activities	-50,989	-18,477
Cash flow from financing activities
Repayment of term loan		-20,614
Repayment of Los Alamos County loan	-8,466	-8,054
Proceeds from Common stock units issued	3,836,133
Share issue expenses	-314,541
Proceeds from warrants exercised	400
Series A Preferred Stock dividends paid	-48,300
Net cash provided by (used in) financing activities	3,465,226	-28,668
Net increase in cash	2,511,618	4,723,548
Cash at the beginning of the period	6,472,393	519,733
Cash at the end of the period	8,984,011	5,243,281
Cash paid for:
Interest	2,175	6,253
Income taxes
Non-cash investing and financing activities:
Common stock issued in exchange for Series B Preferred stock	2,134
Common stock issued in lieu of series B Preferred stock dividends	978,417
Accrued Series A Preferred stock dividends	11,910	11,910
Accrued Series B Preferred stock dividends	$48,745	$138,084

General_Information

General Information	3 Months Ended
	Mar. 31, 2015
General Information [Abstract]
GENERAL INFORMATION	1.	GENERAL INFORMATION
	XRpro Sciences (formerly known as Caldera Pharmaceuticals, Inc.) (“the Company”, “we”, “us”, “our”) is a Delaware corporation. The principal office is located in Cambridge, Massachusetts. The Company was incorporated in November 2003.
	The Company uses proprietary x-ray fluorescence technology called XRpro® to deliver ion channel screening, ion channel kinetics and custom screening services to our customers. Our proprietary technology detects and quantitatively analyzes the x-ray signature of each element with an atomic number greater than 12; we combine the flexibility of the analysis with patented sample processing to address a wide range of ion channel and other biological targets.
	The Company has generated the majority of its revenues to date through Government research contracts and Government grants utilizing its proprietary x-ray fluorescence technology.

Accounting_Policies_and_Estima

Accounting Policies and Estimates	3 Months Ended
	Mar. 31, 2015
Accounting Policies and Estimates [Abstract]
ACCOUNTING POLICIES AND ESTIMATES	2.	ACCOUNTING POLICIES AND ESTIMATES
	General
	The following (a) consolidated balance sheets as of March 31, 2015 (unaudited) and December 31, 2014, which have been derived from audited consolidated financial statements, and (b) the unaudited interim statements of operations and cash flows of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2014 included in the Company’s Form 10-K, filed with the Securities and Exchange Commission (“SEC”).
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).
	In the opinion of management, all adjustments necessary to fairly present the results for the interim periods presented have been made. All adjustments made are of a normal and recurring nature and no non-recurring adjustments have been made in the presentation of these interim financial statements.
	All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.
	Consolidation
	The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries in which it has a majority voting interest. Investments in affiliates are accounted for under the cost method of accounting, where appropriate. All significant inter-company accounts and transactions have been eliminated in the condensed consolidated financial statements. The entities included in these condensed consolidated financial statements are as follows:
	XRpro Sciences, Inc. - Parent Company
	XRpro Corp. – Wholly owned subsidiary
	Caldera Discovery, Inc – Wholly owned subsidiary (formed on March 27, 2015)
	Estimates
	The preparation of these unaudited condensed consolidated financial statements in accordance with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts and recovery of long-lived assets. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the allowance for doubtful accounts, the useful life of plant and equipment and intangible assets, and assumptions used in assessing impairment of long-term assets and the assumptions used in determining percentage of completion on our long-term contracts.
	Contingencies
	Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.
	Fair value of financial instruments
	The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	The carrying amounts reported in the balance sheets for cash, accounts receivable, loans payable, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with the accounting guidance.
	ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.
	Reporting by segment
	No segmental information is presented as the Company only has one significant reporting segment that is Government Revenues.
	Intangible assets
	All of our intangible assets are subject to amortization. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. Where intangibles are deemed to be impaired we recognize an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.
	a)    Patents and License Agreements
	Patents and License agreements acquired by the Company are reported at acquisition value less accumulated amortization and impairments.
	b)    Amortization
	Amortization is reported in the income statement on a straight-line basis over the estimated useful life of the intangible assets, unless the useful life is indefinite. Amortizable intangible assets are amortized from the date that they are available for use. The estimated useful life of the patents and license agreement is twenty years which is the term of the patents and patents supporting the underlying license agreements
	Plant and equipment
	Plant and equipment is stated at cost less accumulated depreciation.  Depreciation is computed using straight-line method over the estimated useful lives of the assets. The estimated useful lives of the assets are as follows:
	Leasehold improvements			5 Years
	Laboratory equipment			7 Years
	Furniture and fixtures			10 Years
	Computer equipment			3 Years
	The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition.
	We examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. We recognize an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
	Concentrations of credit risk
	The Company’s operations are carried out in the USA. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the USA and by the general state of the economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, and rates and methods of taxation, among other things.
	Concentration of major customers
	The Company currently derives substantially all of its revenues from Government research contracts and Government grants.
	These Government research contracts are primarily from two government agencies: The Department of Defense and the National Institutes of Health. The granting of research contracts from Government agencies is a competitive process and there is no certainty that we will be awarded future contracts, which may cause our revenue to fluctuate from year to year. Furthermore, Government grants are subject to audits by the granting agency. If such audits were to determine that expenditures of the grant funds did not meet the applicable criteria, these amounts could be subject to retroactive adjustment and refunded to the granting agency.
	Total revenues by customer type are as follows:
			Three months ended		Three months ended
			March 31,		March 31,
			2015		2014
	National Institutes of Health		$	30,653	$	254,220
			$	30,653	$	254,220
	Accounts receivable and other receivables
	We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. As a basis for accurately estimating the likelihood of collection of our accounts receivable, we consider a number of factors when determining reserves for uncollectable accounts. We believe that we use a reasonably reliable methodology to estimate the collectability of our accounts receivable. We review our allowances for doubtful accounts on a regular basis. We also consider whether the historical economic conditions are comparable to current economic conditions. If the financial condition of our customers or other parties that we have business relations with were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.
	The balance of the receivables provision as at March 31, 2015 and December 31, 2014 was $19,084. The amount charged to bad debt provision for the three months ended March 31, 2015 and 2014 was $0 and $0, respectively.
	Cash and cash equivalents
	For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with two financial institutions in the USA.
	Revenue recognition
	Revenue sources consist of government grants, government contracts and commercial development contracts.
	We account for our long-term Firm Fixed Price Government contracts and grants associated with the delivery of research on drug candidates and the development of drug candidates using the percentage-of-completion accounting method. Under this method, revenue is recognized based on the extent of progress towards completion of the long-term contract.
	We generally use the cost-to-cost measure of progress for all of our long-term contracts, unless we believe another measure will produce a more reliable result. We believe that the cost-to-cost measure is the best and most reliable performance indicator of progress on our long-term contracts as all our contract estimates are based on costs that we expect to incur in performing our long-term contracts and we have not experienced any significant variations on estimated to actual costs to date. Under the cost-to-cost measure of progress, the extent of progress towards completion is based on the ratio of costs incurred-to-date to the total estimated costs at the completion of the long-term contract. Revenues, including estimated fees or profits are recorded as costs are incurred.
	When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on the contract is recorded in the period the loss is determined.
	To a much lesser extent, we enter into fixed fee commercial development contracts that are not associated with the delivery of feasible research on drug candidates and the development of drug candidates. Revenue under such contracts is generally recognized upon delivery or as the development is performed.
	Sales and Marketing
	Sales and marketing expenses are minimal at present. These costs, if any, are expensed as incurred and included in Selling, general and administrative expenses. The Company expects to incur sales and marketing expenses in future periods to promote its services to drug discovery enterprises.
Research and Development
The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred.  Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, the payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the license period or the patent life.
The amount expensed for unrecovered research costs, included in Selling, general and administrative expenses during the three months ended March 31, 2015 and 2014 was $75,034 and $72,403, respectively.
Patent Costs
Legal costs in connection with approved patents and patent applications are expensed as incurred and classified as Selling, general and administrative expense in our condensed consolidated statements of operations.
Share-Based Compensation
Share-based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee's requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2015 and 2014 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with market or performance conditions.
Income Taxes
The Company utilizes ASC 740, Accounting for Income Taxes, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
Net income (loss) per Share
Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the period.
Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.
Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share).
Related parties
Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company shall disclose all related party transactions. All transactions shall be recorded at fair value of the goods or services exchanged. Property purchased from a related party is recorded at the cost to the related party and any payment to or on behalf of the related party in excess of the cost is reflected as a distribution to the related party.
Derivative Liabilities
ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.
The Company had no derivative liabilities as of March 31, 2015.
Convertible Instruments
The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities”.
Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument”.
The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note.
ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.
Recent accounting pronouncements
In January 2015, the FASB issued ASU No. 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” This ASU eliminates from U.S. GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. We do not expect the adoption of ASU 2015-01 to have a material effect on our financial position, results of operations or cash flows.
In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The ASU focuses on the consolidation evaluation for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. In addition to reducing the number of consolidation models from four to two, the new standard simplifies the FASB Accounting Standards Codification and improves current U.S. GAAP by placing more emphasis on risk of loss when determining a controlling financial interest, reducing the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity (“VIE”), and changing consolidation conclusions for companies in several industries that typically make use of limited partnerships or VIEs. The ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not expect the adoption of ASU 2015-02 to have a material effect on our financial position, results of operations or cash flows.
In April 2015, FASB issued Accounting Standards Update (“ASU”) No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, is to simplify presentation of debt issuance costs by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The ASU does not affect the recognition and measurement guidance for debt issuance costs. For public companies, the ASU is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early application is permitted. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.
In April 2015, FASB issued Accounting Standards Update No. 2015-04, Compensation – Retirement Benefits (Topic 715): Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets, permits the entity to measure defined benefit plan assets and obligations using the month-end that is closest to the entity’s fiscal year-end and apply that practical expedient consistently from year to year. The ASU is effective for public business entities for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early application is permitted. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.
In April 2015, FASB issued Accounting Standards Update No. 2015-05, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees paid in a Cloud Computing Arrangement, provides guidance to customers about whether a cloud computing arrangement includes a software license. If such an arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the arrangement does not include a software license, the customer should account for it as a service contract. For public business entities, the ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015. Early application is permitted. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.
In April 2015, FASB issued Accounting Standards Update No. 2015-06, Earnings Per Share (Topic 260): Effects on Historical Earnings per Unit of Master Limited Partnership Dropdown Transactions, specifies that, for purposes of calculating historical earnings per unit under the two-class method, the earnings (losses) of a transferred business before the date of a drop down transaction should be allocated entirely to the general partner. In that circumstance, the previously reported earnings per unit of the limited partners (which is typically the earnings per unit measure presented in the financial statements) would not change as a result of the dropdown transaction. Qualitative disclosures about how the rights to the earnings (losses) differ before and after the dropdown transaction occurs for purposes of computing earnings per unit under the two-class method also are required. The ASU is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Earlier application is permitted. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.
Any new accounting standards, not disclosed above, that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

Liquidity

Liquidity	3 Months Ended
	Mar. 31, 2015
Liquidity [Abstract]
LIQUIDITY	3.	LIQUIDITY
	The Company recently concluded a private placement offering with gross proceeds of $8,855,000 (See note 9 below) providing the Company with sufficient capital resources to meet its projected cash flow requirements in conducting its operations for at least the next twelve month period commencing on March 31, 2015. However there can be no assurance that additional and unforeseen non-recurring expenses will not arise during the next twelve month period or that the Company will be successful in completing its business development plan.

Intangible_Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2015
Intangible Assets [Abstract]
INTANGIBLE ASSETS	4.	INTANGIBLE ASSETS
	Patents and Licenses
	In terms of an Exclusive Patent License agreement (“License”) covering national and international patents entered into with the Los Alamos National Security LLC (“the Licensor”) dated September 8, 2005, the Company has the exclusive right to the use of certain patents. On October 15, 2014, the national and international patents owned by Los Alamos National Security and previously licensed to the Company were assigned to the Company.
	On January 29, 2015, the Company sent a notice to LANS informing them that upon the assignment of all the patents underlying the License Agreement on October 15, 2014, that the license agreement was terminated ab Initio and that the 90 day notice period was waived, alternatively the letter serves as our 90 day notice period. No provision for license fee payments have been made for the three months ended March 31, 2015.
	The patents consist of the following:
	●	Method for Detecting Binding Events Using Micro X-Ray Fluorescence Spectrometry;
	●	Flow Method and Apparatus for Screening Chemicals Using Micro X-Ray Fluorescence;
	●	Method and Apparatus for Detecting Chemical Binding;
	●	Drug Development and Manufacturing.
	●	Advanced Drug Development and Manufacturing (The Licensor assigned its rights to this application to the Company, which already owned rights to this patent assigned to the Company by inventors currently and previously employed by the Company).
	●	Well Plate – apparatus for preparing samples for measurement by x-ray fluorescence spectrometry. Patent filed August 15, 2008
	●	Method and Apparatus for measuring Protein Post Translational Modification. Patent filed September 26, 2008.
	●	Method and Apparatus for Measuring Analyte Transport across barriers. Patent filed July 1, 2009.
	●	Advanced Drug Development and Manufacturing.
	The Company has various other patents pending or registered in its name. These patents have been internally generated and all costs associated with the research and development of these patents has been expensed.
	Patents and licenses consist of the following:
			March 31,			December 31,
			2015			2014
			(unaudited)
	Patents and Licenses, at cost		$	972,000		$	972,000
	Less: Accumulated amortization			(493,714	)		(480,793	)
			$	478,286		$	491,207
	The aggregate amortization expense charged to operations was $12,921 and $12,921 for the three months ended March 31, 2015 and 2014, respectively.  The amortization policies followed by the Company are described in Note 2.
	Amortization expense for future periods is summarized as follows:
			Amount
	Remainder of 2015		$	38,763
	2016			51,684
	2017			51,684
	2018			51,684
	2019 and thereafter			284,471
	Total		$	478,286

Plant_and_Equipment

Plant and Equipment	3 Months Ended
	Mar. 31, 2015
Plant and Equipment [Abstract]
PLANT AND EQUIPMENT	5.	PLANT AND EQUIPMENT
	Plant and equipment consists of the following:
			March 31,			December 31,
			2015			2014
			(unaudited)
	Leasehold improvements		$	6,393		$	6,393
	Furniture and fittings			26,148			26,148
	Laboratory equipment			1,011,013			965,811
	Computer equipment			38,236			32,459
	Total			1,081,790			1,030,811
	Accumulated depreciation			(581,216	)		(549,160	)
			$	500,574		$	481,651
	The aggregate depreciation charge to operations was $32,226 and $26,959 for the three months ended March 31, 2015 and 2014, respectively. The depreciation policies followed by the Company are described in Note 2.

Other_Payables_and_Accrued_Exp

Other Payables and Accrued Expenses	3 Months Ended
	Mar. 31, 2015
Other Payables and Accrued Expenses [Abstract]
OTHER PAYABLES AND ACCRUED EXPENSES	6.	OTHER PAYABLES AND ACCRUED EXPENSES
			March 31,		December 31,
			2015		2014
			(unaudited)
	Credit card liabilities		$	4,018	$	10,393
	Vacation and Sick Pay accrual			133,210		125,394
	Other payables			490,625		490,625
	Payroll liabilities			98,514		66,731
	Other			78,731		92,110
			$	805,098	$	785,253
	The other payables consist of an accrual for the anticipated judgment liability handed down in the “Litigation with the estate of Sigmund Eisenschenk”, on March 16, 2015 as disclosed in note 15 below.

Loans_Payable

Loans Payable	3 Months Ended
	Mar. 31, 2015
Loans Payable [Abstract]
LOANS PAYABLE	7.	LOANS PAYABLE
			March 31,		December 31,
			2015		2014
			(unaudited)
	Short term portion
	Los Alamos County project participation loan		$	34,985	$	34,552
	Long term portion
	Los Alamos County project participation loan			133,591		142,502
	Total		$	168,576	$	177,054
	The amortization of the principal outstanding on the loans payable is as follows:
			Amount
	Within 1 year		$	34,985
	1 to 2 years			36,775
	2 to 3 years			38,657
	3 to 4 years			40,634
	Thereafter			17,525
	Total		$	168,576
	Los Alamos County project participation loan
	The Company entered into a Project Participation Agreement (as Amended) and a Loan Agreement with the Incorporated County of Los Alamos as of September 21, 2006. The Agreement provided for funding up to a maximum of $2,200,000 for the construction of a building and purchase of equipment. The maximum amount of equipment to be funded out of the total available loan of $2,200,000 was $625,000. The term of the loan is 13 years. The loan agreement provided for no repayments for 36 months with 120 equal monthly repayments commencing on September 21, 2009. The interest rate on the loan is 5% per annum. The assets funded in terms of the Project Participation Agreement and the Loan Agreement is to be used as security for the balance of the loan outstanding. The Company made use of the loan to purchase assets amounting to $302,009 during the 2007 financial year. Repayments of the loan commenced on September 21, 2009 at an interest rate of 5% per annum with equal monthly repayments of $3,547, inclusive of interest. The Company owed $168,576 and $177,054 as of March 31, 2015 and December 31, 2014, respectively.

Preferred_Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2015
Common Stock and Preferred Stock [Abstract]
PREFERRED STOCK	8	PREFERRED STOCK
	Preferred Stock consists of 10,000,000 authorized preferred shares of $0.001 par value each, of which 400,000 are designated as Series A 8% convertible redeemable preferred shares of $0.001 each and 3,000,000 are designated as Series B convertible  preferred shares of $0.001 each, with the remaining 6,600,000 preferred shares remaining undesignated.
	Series A 8% Convertible, Redeemable Preferred Stock (“Series A Stock”)
	Series A Stock consists of 400,000 designated shares of $0.001 par value each, 105,000 shares issued and outstanding as of March 31, 2015 and December 31, 2014.
	Conversion
	The Series A Stock will convert to common stock of the Company at a price of $11.40 per share of Common Stock subject to adjustment for stock splits, stock dividends and any further recapitalizations. The Series A Stock is subject to voluntary conversion at the option of the stockholder at any time and mandatory conversion at the option of the Company provided the Company’s common stock is trading on a recognized stock exchange or Over the Counter Bulletin Board and the volume weighted average price of the Company’s common stock is at least $20 per share, subject to stock splits, stock dividends and recapitalizations.
	Warrants
	The original holders of Series A Stock had received warrants to purchase 170,804 shares of the Company’s common stock at an exercise price of $11.40 per share. The warrants expire five years after date of issuance. In terms of the exchange agreement entered into with the Company on April 30, 2013, these warrants remain in place. These warrants are not transferable without the consent of the Company and an opinion of counsel satisfactory to the Company.
	Redemption
	Should the Company receive net proceeds of at least $3 million from litigation proceedings against the Regents of the University of California and Los Alamos National Security; the remaining Series A stockholders will have the option to have the Company redeem the Series A Stock equal to 130% of the initial investment in the Company by the stockholder, which amounted to $210,000. This value differs from the carrying value of the Series A Stock of $133,350 which was valued using the Black-Scholes valuation model at the time of exchanging common stock for Series A Stock. The Company also has the option to redeem the Series A Stock at a price equal to 130% of the initial investment in the Company by the stockholder at any time after giving the investors notice and allowing them to exercise their conversion rights into common stock 30 days after notice has been received.
	Liquidation
	The liquidation rights of the Series A Stock is the greater of $5.70 per share plus any unpaid dividends or an amount that would have been payable had all shares of Series A Stock converted into common stock immediately prior to liquidation.
	Dividends
	The Series A Stock carries an 8% cumulative, non-compounded dividend payable on January 31st, each year in cash or in kind at the option of the Series A stockholder. For any other dividends or distributions, the Series A Stock is treated on an as- converted basis.
	An accrual for Series A Stock dividends of $11,910 and $11,910 was made for the three months ended March 31, 2015 and 2014, respectively.
	During the three months ended March 31, 2015 and the year ended December 31, 2014, the Company paid $48,300 and $29,774 of accrued Series A stock dividends.
	Series B Convertible Preferred Stock (“Series B Stock”)
	Series B Stock consists of 3,000,000 designated shares of $0.001 par value each and 0 and 2,133,947 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively.
	On January 31, 2015, in accordance with the terms of the various exchange agreements (the “Series B Preferred Stock Exchange Agreements”) entered into between the Company, and the holders of its outstanding Series B Preferred Stock, each holder of Series B Preferred Stock  exchanged all of their shares of Series B Preferred Stock for the number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) determined by dividing the sum of the amount of the holder’s initial investment in the Series B Preferred Stock, plus all accrued and unpaid dividends owed to the holder, by $3.50. All 2,133,947 outstanding shares of the Company’s Series B Preferred Stock, including accrued and unpaid dividends thereon, were exchanged for 1,803,820 shares of the Common Stock, resulting in no shares of Series B Preferred Stock remaining outstanding.
	The following is a summary of material provisions of the Series B Stock as set forth in the Certificate of Designations.
	Conversion
	Subject to adjustment as more fully described herein, each Series B Stock is currently convertible at the option of the holder into one share of Common Stock. Each Series B Stock (together with any accrued but unpaid dividends thereon) is convertible into shares of Common Stock at the option of the holder at any time at a conversion price per share equal to the sum of the Stated Value and any accrued but unpaid dividends thereon through the date of notice of conversion divided by the Conversion Price, subject to adjustment as described below. The initial Conversion Price shall be equal to the Stated Value. If the Company merges or sells its assets, holders of Series B Stock will be entitled to receive on conversion the securities or property (including cash) of the successor corporation that they would have received as a result of that merger or sale if they had converted immediately beforehand. At any time after the Common Stock is listed on a national securities exchange as defined in the Securities Exchange Act of 1934, the Company may cause the conversion of the Series B Stock, plus accrued but unpaid dividends into shares of Common Stock, each Series B Stock convertible into such number of shares of Common Stock as shall equal the sum of the Stated Value plus any accrued but unpaid dividends through the date of conversion divided by the lower of the then conversion price and the market price of the Company’s Common Stock. Market Price is defined as the average of the reported closing sales price of the Common Stock for each of the five trading days for which a closing sales price is reported immediately preceding the day prior to the conversion.
	Liquidation
	In the event of a liquidation, dissolution or winding up of the Company and other Liquidation Events as defined in the Certificate of Designations, holders of Series B Stock are entitled to receive from proceeds remaining after distribution to the Company’s creditors and prior to the distribution holders of Common Stock or any other class of preferred stock the (x) Stated Value (as adjusted for any stock splits, stock dividends, reorganizations, recapitalizations and the like) held by such holder and (y) all accrued but unpaid dividends on such shares.
	Anti-Dilution
	If the Company issues Common Stock or securities convertible, exercisable or exchangeable into Common Stock for a purchase price of less than $5.00 per share then the holders of the Series B Stock will be entitled to a weighted-average” adjustment in the number of common shares that their Series B Stock can be converted into; provided, however, that there will be no adjustment to the number of shares of Common Stock that the Series B Stock can be converted into for (i) issuance or sale of Common Stock or options or other awards under the Corporation’s equity incentive plans or programs not to exceed 1,000,000 shares of Common Stock; (ii) issuance or sale of preferred stock or Common Stock issuable upon conversion, exchange or exercise of the Series A Stock or Series B Stock, the Bridge Notes, the Warrants issued in connection with the exchange of the Bridge Notes, the Warrants issued in connection with the issuance of the Series B Stock to the holders thereof, any Warrants issued to the Placement Agent or its designees in connection with the issuance of the Series B Stock or as an advisory fee or any other convertible securities or warrants outstanding on the date hereof; (iii) issuance of equity securities or rights to purchase equity securities issued in connection with commercial property or lease transactions that are approved by the Board of Directors; (iv) issuance of equity securities or rights to purchase equity securities issued for consideration other than cash pursuant to a merger, consolidation, acquisition or similar business combination approved by the Board of Directors; (v) issuance of securities to an entity as a component of any business relationship with such entity primarily for the purpose of (A) joint venture, technology or licensing development activities; (B) distribution, supply or manufacture of the Company’s products or services; or (C) any other arrangements involving corporate partners primarily for purposes other than raising capital, the terms of which business relationship with such entity are approved by the Board of Directors; and (vi) issuance of stock pursuant to a stock dividend or stock split.
	Voting
	Except as otherwise required by law and except as set forth below, holders of Series B Stock will, on an as-converted basis, vote together with the Common Stock as a single class. Each holder of Series B Stock is entitled to cast the number of votes equal to two times the number of shares of Common Stock into which such shares of Series B Stock could be converted at the record date for determining stockholders entitled to vote at the meeting. The approval by holders of a majority of the Series B Stock, voting separately as a class, will be required for the creation of any class or series of preferred stock ranking senior to or pari passu with the Series B Stock as to payments of dividends or upon the liquidation of the Company.
	Financials
	As soon as practicable after the filing of the Company’s Quarterly Report on Form 10-Q and its Annual Report on Form 10-K, the Holders of the Series B Stock are entitled to receive, upon request, a consolidated balance sheet of the Company, if any, as of the end of such fiscal year or quarter, and consolidated statements of operations and consolidated statements of cash flows and stockholders’ equity of the Company, if any, for such year or quarter, prepared in accordance with generally accepted accounting principles and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail.
	Dividends
	Series B Stock accrue dividends at the rate per annum equal to (i) 8% of the sum of (x) the Stated Value and (y) the amount of accrued and unpaid dividends payable, out of funds legally available for payment, on January 31st of each year, if paid in cash, or (ii) 10% of the sum of (x) the Stated Value and (y) the amount of accrued and unpaid dividends payable, out of funds legally available for payment, on January 31st of each year, if paid in shares of Common Stock, based upon a price of $5.00 per share of Common Stock. The Company shall have the option, to pay any such dividends in cash or shares of Common Stock. Such dividends shall be in preference and priority to any payment of any dividend on Common Stock, or any other class of preferred stock. Dividends are cumulative.
	An accrual for Series B Stock dividends of $48,745 and $138,083 was made for the three months ended March 31, 2015 and 2014, respectively.

Common_Stock

Common Stock	3 Months Ended
	Mar. 31, 2015
Common Stock and Preferred Stock [Abstract]
COMMON STOCK	9	COMMON STOCK
	Common stock consists of 50,000,000 authorized shares of $0.001 each, 6,700,707 and 3,780,847 shares issued and 6,373,707 and 3,453,847 shares outstanding as of March 31, 2015 and December 31, 2014, respectively.
	On December 31, 2014, we  sold in a private placement offering (the “Private Placement”) 716,981 units at a per unit price of $7.00, each unit (the “Units”) consisting of four shares of Common Stock, prior to the reverse stock split and a five year warrant (the “Private Placement Warrants”) to acquire one share of Common Stock at an exercise price of $1.75 per share, prior to the reverse stock split, to accredited investors for aggregate cash proceeds of $5,018,867 pursuant to a master purchase agreement entered into with the investors (the ”Purchase Agreements”). On January 7, 2015, we consummated the second closing in the Private Placement and sold an additional 548,019 Units for additional aggregate cash proceeds of $3,836,133. The aggregate total number of Units sold in both closings was 1,265,000 Units, prior to the reverse stock split, for total gross proceeds of $8,855,000. The number of shares of common stock issued and five year warrants to acquire one share of common stock in terms of the private placement amounted to approximately 2,530,000 and 632,531, respectively, after rounding up each fractional share or warrant after giving effect to the reverse stock split. In connection with the Private Placement, we have prepared and filed a registration statement with the SEC for the resale by the purchasers of all of the Common Stock and the Common Stock underlying the Private Placement Warrants and all shares of Common Stock issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect thereto.  In addition, we registered the shares of Common Stock underlying the Placement Agent Warrants.
	The Company retained Taglich Brothers, Inc., as the exclusive placement agent for the Offering. In connection therewith, the Company agreed to pay the placement agent an eight percent (8%) commission from the gross proceeds of the Offering ($708,400) and reimbursed approximately $35,000 in respect of out of pocket expenses, FINRA filing fees and related legal fees incurred by the placement agent in connection with the Offering. As of March 31, 2015 the Company has paid and recorded $753,551 as share issue expenses related to common stock issuances on December 31, 2014 and January 7, 2015.
	On January 31, 2015, in accordance with the terms of the various exchange agreements (the “Series B Preferred Stock Exchange Agreements”) entered into between the Company, and the holders of its outstanding Series B Preferred Stock, each holder of Series B Preferred Stock  exchanged all of their shares of Series B Preferred Stock for the number of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) determined by dividing the sum of the amount of the holder’s initial investment in the Series B Preferred Stock, plus all accrued and unpaid dividends owed to the holder, by $3.50. All 2,133,947 outstanding shares of the Company’s Series B Preferred Stock, including accrued and unpaid dividends thereon, were exchanged for 1,803,820 shares of the Common Stock, resulting in no shares of Series B Preferred Stock remaining outstanding.

Warrants

Warrants	3 Months Ended
	Mar. 31, 2015
Warrants [Abstract]
WARRANTS	10	WARRANTS
	On January 7, 2015, the Company consummated the second closing in the Offering and sold an additional 548,019 Units, each unit including a five year warrant (“Offering Warrant”) to acquire one share of the Company’s Common Stock at an exercise price of $1.75 per share, prior to the reverse stock split, after the reverse stock split the number of warrants outstanding to acquire one share of the Company’s Common stock was reduced to 274,019 warrants exercisable at a price of $3.50 per share. These Offering Warrants contain cashless exercise provisions. In addition, the Company also issued the placement agent a five-year warrant exercisable for an aggregate amount of 253,000 shares of Common Stock at an exercise price of $3.50 per share and an advisory warrant exercisable for an additional 100,000 shares of Common Stock at an exercise price of $3.50 per share (the “Placement Agent Warrants”). The Company also filed a registration statement with the SEC for the resale by the purchasers of all of the Shares and the Common Stock underlying the Offering Warrants and all shares of Common Stock issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect thereto.  In addition, the Company registered the shares of Common Stock underlying the Placement Agent Warrants.
	On January 31, 2015 the Company entered into: (i) exchange agreements (the “Series B Preferred Stock and Warrant Exchange Agreements”) with the holders of the warrants that were issued as part of the private placement of the Series B Preferred Stock (the “Existing Series B Warrants”) to exchange both Series B Preferred Stock for Common Stock and their 635,834 Existing Series B Warrants, (ii) exchange agreements (the “Bridge Warrant Exchange Agreements”) with the holders (the “Bridge Warrant Holders”) of its 150,000 warrants that were issued in connection with the Company’s bridge note financing (the “Existing Bridge Warrants”), and (iii) exchange agreements (the “Placement Agent Exchange Agreements”) with Taglich Brothers, Inc. and its designees (the “Placement Agent Warrant Holders”) that were issued 143,401 warrants as compensation for the placement agent services provided in connection with the private placement of the Series B Preferred Stock (the “Existing Placement Agent Warrants”). The Existing Series B Warrants, the Existing Bridge Warrants and the Existing Placement Agent Warrants are collectively referred to as the “Existing Warrants”. Pursuant to the terms of the Bridge Warrant Exchange Agreements, the Series B Preferred Stock and Warrant Exchange Agreements and the Placement Agent Exchange Agreements, the Existing Bridge Warrants, the Existing Series B Warrants and the Existing Placement Agent Warrants were exchanged for new warrants (the “Series B Exchange Warrants,” the “Bridge Exchange Warrants” and the “Placement Agent Exchange Warrants”), which have substantially similar terms to the Existing Warrants except that: (i) the exercise price of the Series B Exchange Warrants, the Bridge Exchange Warrants and the Placement Agent Exchange Warrants are 30% less than the exercise price of the Existing Warrants for which they were exchanged (such that: (x) the 150,000 Bridge Exchange Warrants have an exercise price of $4.20; (y) the 143,401 Placement Agent Exchange Warrants have an exercise price of $3.85; and (z) the 635,834 Series B Exchange Warrants have an exercise price of $3.50); (ii) the Bridge Exchange Warrants, the Series B Exchange Warrants and the Placement Agent Exchange Warrants do not contain anti-dilution price protection for issuances of securities at per share prices that are lower than the exercise price; (iii) the Bridge Exchange Warrants, the Series B Exchange Warrants and the Placement Agent Exchange Warrants are assignable by their holders; and (iv) the Bridge Exchange Warrants, the Series B Exchange Warrants and the Placement Agent Exchange Warrants provide for certain buy-in-rights in the event that the Company fails to deliver shares of Common Stock underlying the warrant in a timely manner.
	Effective January 1, 2015, the Company issued 32,500 warrants exercisable at $3.50 per share to BluePrint Media, LLC, in terms of an agreement entered into to provide investor relations consulting services to the Company. Included in stock compensation charge is an amount of $94,095 which represents the value of these warrants determined using a Black-Scholes valuation model.
	The following weighted average assumptions were used in the Black-Scholes valuation model:
			Three months
			ended  March 31,
			2015
	Calculated stock price		$	3.5
	Risk-free interest rate			2.12	%
	Expected life of options			5 Years
	Expected volatility of the underlying stock			119.3	%
	Expected dividend rate			0	%
	On March 4, 2015, the holders of the 20,000 Placement Agent advisory warrants exercisable at $0.02 per share exercised their warrants for cash proceeds of $400.
	The following table summarizes warrants outstanding and exercisable as of March 31, 2015:
					Warrants Outstanding						Warrants Exercisable
	Exercise Price				Number of		Weighted average remaining		Weighted		Number of		Weighted
					shares		contractual		Average		Shares		Average
							years		Exercise Price				exercise Price
	$	3.5				1,653,865		4.62				1,653,865
	$	4				7,500		1.59				7,500
	$	4.2				150,000		2.86				150,000
	$	3.85				143,401		1				143,401
	$	11.4				192,204		1.19				192,204
						2,146,970		3.94	$	4.28		2,146,970	$	4.28

Stock_Based_Compensation

Stock Based Compensation	3 Months Ended
	Mar. 31, 2015
Stock Based Compensation [Abstract]
STOCK BASED COMPENSATION	11	STOCK BASED COMPENSATION
	In October 2005, the Company's Board of Directors adopted the Caldera Pharmaceuticals, Inc. 2005 Stock Option Plan (the "Plan"), which permits awards of incentive and nonqualified stock options and other forms of incentive compensation to employees and non-employees such as directors and consultants. The Board has set aside 1,500,000 shares of common stock for issuance upon exercise of grants made under the Plan. Options granted under the Plan vest either immediately or over a period of up to two years, and expire 1 year to 10 years from the grant date. At March 31, 2015, 519,048 shares were available for future grant under the Incentive Plan.
	On March 12, 2015, the Board of Directors authorized the re-pricing of 56,770 Stock options, post reverse stock split, issued to certain scientific employees to recognize their contribution to the commercialization efforts of the Company. These Stock options were originally exercisable at priced of $11.40 per share which exercise price has been reduced to $4.00 per share. These Stock options are fully vested and resulted in a stock option based compensation charge of $32,375 for the three months ended March 31, 2015.
	On January 7, 2015, in terms of an employment agreement entered into with Richard Cunningham, our new CEO, a further 250,000 ten-year stock options excisable at $3.50 per share were issued to him. These options vest as follows: 50,000 on November 24, 2015, 150,000 vest equally over a period of 36 months commencing on November 24, 2015 and 50,000 on November 24, 2018.
	On February 2, 2015, a further 5,000 ten-year stock options were awarded to a new employee, exercisable at $3.50 per share and vesting as to 1,250 stock options annually on the anniversary date of employment over the next four years.
	Stock option based compensation expense totaled $83,392 and $186,523 for the three months ended March 31, 2015 and 2014, respectively. The Company expenses the value of stock options on a straight line basis over the life of the options. The fair value of the options granted is determined using the Black-Scholes option-pricing model.
	The following weighted average assumptions were used for the three months ended March 31, 2015:
			Three months ended
			March 31,
			2015
	Calculated stock price		$	3.50 – 4.00
	Risk-free interest rate			1.68% to 2.10	%
	Expected life of options			1- 10 Years
	Expected volatility of the underlying stock			119.3	%
	Expected dividend rate			0	%
	As noted above, the fair value of stock options is determined by using the Black-Scholes option-pricing model. For all options granted since October 1, 2005 the Company has generally used option terms of between 1 to 10 years. The volatility of the common stock is estimated using historical data of companies similar in size and in the same industry as the Company.  The risk-free interest rate used in the Black-Scholes option-pricing model is determined by reference to historical U.S. Treasury constant maturity rates with maturities approximate to the life of the options granted. An expected dividend yield of zero is used in the option valuation model, because the Company does not expect to pay any cash dividends in the foreseeable future. As of March 31, 2015, the Company does not anticipate any awards will be forfeited in the calculation of compensation expense due to the limited number of employees that receive stock option grants.
	No options were exercised for the three months ended March 31, 2015 and the year ended December 31, 2014, respectively.
	We canceled options exercisable for 0 and 255,262 shares of common stock for the three months ended March 31, 2015 and the year ended December 31, 2014, respectively, held by employees whose service to our company terminated during those respective periods. The shares underlying such options were returned to and are available for re-issuance under the 2005 Plan pursuant to the terms described above.
	A summary of all of our option activity during the period January 1, 2014 to March 31, 2015 is as follows:
			Shares				Exercise				Weighted
							Price per				Average
							Share				Exercise Price
	Outstanding January 1, 2014			825,214			$	0.40  - 11.42			$	4.62
	Granted			156,000				5				5
	Forfeited/Cancelled			(255,262	)			5.00 - 11.42				5.26
	Exercised			-				-				-
	Outstanding December 31, 2014			725,952			$	0.40  - 11.42			$	3.82
	Granted			255,000				3.5				3.5
	Forfeited/Cancelled			-				-				-
	Exercised			-				-				-
	Outstanding March 31, 2015			980,952			$	0.40 - 11.42			$	3.82
	Stock options outstanding as of March 31, 2015 and December 31, 2014, as disclosed in the above table, have an intrinsic value of $345,750.
	The following tables summarize information about stock options outstanding as of March 31, 2015:
					Options Outstanding										Options Exercisable
	Exercise Price				Number of				Weighted average				Weighted		Number of		Weighted
					shares				remaining				Average		Shares		Average
									contractual years				Exercise Price				exercise Price
	$	0.4				15,000				7.09						15,000
	$	2.2				110,000				5.92						110,000
	$	3				312,500				7.96						312,500
	$	3.5				255,000				9.78						-
	$	4				64,270				3.26						63,020
	$	5				178,500				6.68						75,801
	$	11.42				45,682				3.91						45,682
						980,952				7.46			$	3.82		622,003	$	3.76
	The weighted-average grant-date fair values of options granted during the three months ended March 31, 2015 and the year ended December 31, 2014 was $844,577 ($3.31 per option) and $302,080 ($1.94 per option), respectively. As of March 31, 2015 there were unvested options to purchase 358,949 shares of common stock. Total expected unrecognized compensation cost related to such unvested options is $989,391, which is expected to be recognized over a period of 46 months.

Net_Income_Loss_Per_Common_Sha

Net Income (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2015
Net Income (Loss) Per Common Share [Abstract]
NET INCOME (LOSS) PER COMMON SHARE	12	NET INCOME (LOSS)  PER COMMON SHARE
	Basic income (loss) per share is based on the weighted-average number of common shares outstanding during each period. Diluted income (loss) per share is based on basic shares as determined above plus the incremental shares that would be issued upon the assumed exercise of “in-the-money” stock options and warrants using the treasury stock method and the inclusion of all convertible securities, including preferred stock and convertible notes, assuming these securities were converted at the beginning of the period or at the time of issuance, if later. The computation of diluted net income (loss) per share does not assume the issuance of common shares that have an anti-dilutive effect on net income (loss) per share.
	For the three months ended March 31, 2015 the following options, warrants and convertible preferred stock were excluded from the computation of diluted net loss per shares as the result of the computation was anti-dilutive:
			Three months ended
			March 31,
			2015
			(Shares)
	Options to purchase shares of common stock			980,952
	Warrants			2,146,970
	Series A convertible, redeemable preferred stock			105,000
				3,232,922
	For the three months ended March 31, 2014 the computation of basic and diluted earnings per share is as follows:
			For the three months ended
			31-Mar-14
			Income			Shares		Per share amount
	Net income		$	5,420,979
	Preferred stock dividends			(149,993	)
	Basic Earnings per share
	Income available to common stockholders			5,270,986			2,076,760	$	2.54
	Effect of dilutive securities
	Warrants			-			19,823
	Options			-			14,973
	Series A Preferred stock			11,910			52,500
	Series B Preferred stock			138,083			1,066,974
	Diluted Earnings per share
	Income available to common stockholders and assumed conversions		$	5,420,979			3,231,030	$	1.68
	For the three months ended March 31, 2014 options to purchase 699,902 shares of common stock and warrants to purchase 1,128,935 shares of common stock were excluded from the computation of diluted earnings per share as the option and warrant exercise prices was greater than the average market price of the common shares. These options and warrants were still outstanding as of March 31, 2014.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	13	RELATED PARTY TRANSACTIONS
	The majority of the common shares in the Company is owned by Dr. Benjamin Warner, the Chief Scientific Officer. As of March 31, 2015 and December 31, 2014, Dr. Benjamin Warner owned directly and indirectly 27.0% and 46.2%, respectively of the issued and outstanding shares of common stock on an un-diluted basis.
	In terms of an employment agreement entered into with Richard Cunningham, our Chief Executive Officer, stock options to purchase 250,000 shares of the Company’s common stock was awarded to Mr. Cunningham on January 7, 2015, which options vest as follows: (i) Fifty Thousand (50,000) shares shall vest on November 24, 2015; (ii) One Hundred and Fifty Thousand (150,000) shares shall vest monthly on a pro rata basis commencing on December 31, 2015 for a period of forty eight months; and (iii) Fifty Thousand (50,000) shares shall vest on the November 24, 2018. The exercise price for the options is $3.50 per share. Upon a change of control, as defined in the Company’s existing stock option plan, all unvested options issued to the Mr. Cunningham shall become fully vested immediately upon the change of control.

Operating_Leases

Operating Leases	3 Months Ended
	Mar. 31, 2015
Operating Leases [Abstract]
OPERATING LEASES	14	OPERATING LEASES
	The Company entered into a laboratory and office lease agreement for 2,813 square feet in Cambridge, Massachusetts effective June 1, 2013. The term of the lease was for a twelve month period which terminated on May 31, 2014. The lease agreement is under renewal discussions for a further eighteen month period, expiring on December 31, 2015 for a monthly rental of approximately $16,600, including estimated operating costs and property taxes. The rental charge for the three months ended March 31, 2015 amounted to $47,798.
	The Company’s office lease in New Mexico terminated in October 2013 and has not been renewed. This lease is ongoing as a month to month lease for $5,075 per month. Rental expense for the three months ended March 31, 2015 was $15,226.
	The Company entered into a new corporate apartment lease commencing on June 1, 2014 for a period of one year for a monthly rental of $2,500 per month. Rental expense for the three months ended March 31, 2015 amounted to $7,500.
	On October 10, 2014, the Company entered into a corporate apartment lease in Cambridge, Massachusetts. The term of the lease is for nine months terminating on July 6, 2015. The monthly rental amounts to $3,351. Rental expense for the three months ended March 31, 2015 amounted to $10,205.
	Future annual minimum payments required under operating lease obligations as of March 31, 2015, are as follows:
			Amount
	2015		$	168,068

Litigation

Litigation	3 Months Ended
	Mar. 31, 2015
Litigation [Abstract]
LITIGATION	15	LITIGATION
	There have been no material litigation developments since the filing of our Annual Report on 10-K for the year ended December 31, 2014 other than as follows:
	Bellows Litigation
	On March 16, 2015, the Company filed a second motion to disqualify the Bellows Law Group, P.C and Bellows & Bellows, P.C.
	On March 23, 2015, the Company filed a motion to dismiss Counts II-IV of the first amended complaint. A clerk’s status date is scheduled for June 23, 2015, at which time a hearing date will be scheduled on the motion to dismiss.
	Redemption Litigation
	On August 25, 2014, Joel Bellows filed a complaint against the Company and Benjamin Warner in the Chancery Division of the Circuit Court of Cook County, Illinois. In the complaint, Bellows alleges that he is entitled to redeem his Series A cumulative preferred stock at a price of $7.41 pursuant to the terms of the Company’s June 24, 2011, private placement memorandum. Bellows alleges that the Company violated his rights under the private placement memorandum by unreasonably and vexatiously denying his request for redemption.
	The hearing on Defendants’ motion to dismiss scheduled for April 29, 2015was cancelled by the Court and the Court requested that the parties submit supplemental briefs to address (a) whether the Court should apply Delaware or Illinois law, and (b) whether paragraph 19 of the Settlement Agreement is a choice of law or choice of forum provision. The hearing is reset to June 5, 2015.
	Litigation with estate of Sigmund Eisenschenk
	On March 27, 2015, the Company and Crane filed a motion to dismiss Counts I and II of the Petition for Citation to Recover and to Stay Counts IV-VI. The motion to dismiss is scheduled for a hearing on May 19, 2015.
	On March 31, 2015, American Millings, QTM Ventures LLC and the supervised administrator, Peter Schmiedel, filed petitions to approve attorneys’ fees and costs in the amount of $158,816.97, $80,603.75 and $37,080.00, respectively. On May 5, 2015, the Company filed its opposition to the fee petitions. A hearing is scheduled for May 19, 2015.
	On April 14, 2015, the Company filed a notice of appeal from the March 16, 2015, orders of the Probate Division of the Circuit Court of Cook County which (1) found that Sigmund Eisenschenk’s rights in the Company’s stock were not collected, recalled, or cancelled, (2) partially vacated the Michael T Lyon or the Michael T Lyon Profit Sharing Plan and Richard Lane’s claims against the Estate, and (3) granted partial summary judgment against the Company and declared that the Estate of Eisenschenk owns no less than 177,500 shares of the Company’s stock, effectively nullifying the original recall by the Company on December 23, 2011 (the 177,500 shares effected by the reverse split will amount to 88,750 shares post reverse split which took place on March 25, 2015).
	On April 14, 2015, the Company filed a motion pursuant to Illinois Supreme Court Rule 305 requesting a stay of enforcement of the orders of March 16, 2015, pending resolution of the appeal. The Company offered to place 177,500 shares of stock in escrow (the 177,500 shares effected by the reverse split will amount to 88,750 shares post reverse split which took place on March 25, 2015) as security in lieu of a bond pending resolution of the appeal. The Estate opposes the Company’s request to deposit shares as collateral and requested that the Court require the posting of a bond. The motion requesting a stay of the March 16, 2015, orders is scheduled for June 1, 2015.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2015
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	16	SUBSEQUENT EVENTS
	Other than disclosed above, the Company has evaluated subsequent events through the date the unaudited condensed consolidated financial statements were available to be issued, and has concluded that no such events or transactions took place that would require disclosure herein.

Accounting_Policies_and_Estima1

Accounting Policies and Estimates (Policies)	3 Months Ended
	Mar. 31, 2015
Accounting Policies and Estimates [Abstract]
General	General
	The following (a) consolidated balance sheets as of March 31, 2015 (unaudited) and December 31, 2014, which have been derived from audited consolidated financial statements, and (b) the unaudited interim statements of operations and cash flows of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of results that may be expected for the year ending December 31, 2015. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2014 included in the Company’s Form 10-K, filed with the Securities and Exchange Commission (“SEC”).
Basis of Presentation	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).
	In the opinion of management, all adjustments necessary to fairly present the results for the interim periods presented have been made. All adjustments made are of a normal and recurring nature and no non-recurring adjustments have been made in the presentation of these interim financial statements.
	All amounts referred to in the notes to the unaudited condensed consolidated financial statements are in United States Dollars ($) unless stated otherwise.
Consolidation	Consolidation
	The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries in which it has a majority voting interest. Investments in affiliates are accounted for under the cost method of accounting, where appropriate. All significant inter-company accounts and transactions have been eliminated in the condensed consolidated financial statements. The entities included in these condensed consolidated financial statements are as follows:
	XRpro Sciences, Inc. - Parent Company
	XRpro Corp. – Wholly owned subsidiary
	Caldera Discovery, Inc – Wholly owned subsidiary (formed on March 27, 2015)
Estimates	Estimates
	The preparation of these unaudited condensed consolidated financial statements in accordance with US GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts and recovery of long-lived assets. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of the financial statements. Significant estimates include the allowance for doubtful accounts, the useful life of plant and equipment and intangible assets, and assumptions used in assessing impairment of long-term assets and the assumptions used in determining percentage of completion on our long-term contracts.
Contingencies	Contingencies
	Certain conditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against and by the Company or unasserted claims that may result in such proceedings, the Company’s management evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.
	If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed. Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.
Fair value of financial instruments	Fair value of financial instruments
	The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
	Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date.
	Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data.
	Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information.
	The carrying amounts reported in the balance sheets for cash, accounts receivable, loans payable, accounts payable and accrued expenses approximate their fair market value based on the short-term maturity of these instruments. The Company did not identify any assets or liabilities that are required to be presented on the balance sheets at fair value in accordance with the accounting guidance.
	ASC 825-10 “Financial Instruments” allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.
Reporting by segment	Reporting by segment
	No segmental information is presented as the Company only has one significant reporting segment that is Government Revenues.
Intangible assets	Intangible assets
	All of our intangible assets are subject to amortization. We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. Where intangibles are deemed to be impaired we recognize an impairment loss measured as the difference between the estimated fair value of the intangible and its book value.
	a)    Patents and License Agreements
	Patents and License agreements acquired by the Company are reported at acquisition value less accumulated amortization and impairments.
	b)    Amortization
	Amortization is reported in the income statement on a straight-line basis over the estimated useful life of the intangible assets, unless the useful life is indefinite. Amortizable intangible assets are amortized from the date that they are available for use. The estimated useful life of the patents and license agreement is twenty years which is the term of the patents and patents supporting the underlying license agreements
Plant and equipment	Plant and equipment
	Plant and equipment is stated at cost less accumulated depreciation.  Depreciation is computed using straight-line method over the estimated useful lives of the assets. The estimated useful lives of the assets are as follows:
	Leasehold improvements		5 Years
	Laboratory equipment		7 Years
	Furniture and fixtures		10 Years
	Computer equipment		3 Years
	The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition.
	We examine the possibility of decreases in the value of fixed assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. We recognize an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Concentrations of credit risk	Concentrations of credit risk
	The Company’s operations are carried out in the USA. Accordingly, the Company’s business, financial condition and results of operations may be influenced by the political, economic and legal environment in the USA and by the general state of the economy. The Company’s results may be adversely affected by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, and rates and methods of taxation, among other things.
Concentration of major customers	Concentration of major customers
	The Company currently derives substantially all of its revenues from Government research contracts and Government grants.
	These Government research contracts are primarily from two government agencies: The Department of Defense and the National Institutes of Health. The granting of research contracts from Government agencies is a competitive process and there is no certainty that we will be awarded future contracts, which may cause our revenue to fluctuate from year to year. Furthermore, Government grants are subject to audits by the granting agency. If such audits were to determine that expenditures of the grant funds did not meet the applicable criteria, these amounts could be subject to retroactive adjustment and refunded to the granting agency.
	Total revenues by customer type are as follows:
		Three months ended		Three months ended
		March 31,		March 31,
		2015		2014
	National Institutes of Health	$	30,653	$	254,220
		$	30,653	$	254,220
Accounts receivable and other receivables	Accounts receivable and other receivables
	We have a policy of reserving for uncollectible accounts based on our best estimate of the amount of probable credit losses in our existing accounts receivable. As a basis for accurately estimating the likelihood of collection of our accounts receivable, we consider a number of factors when determining reserves for uncollectable accounts. We believe that we use a reasonably reliable methodology to estimate the collectability of our accounts receivable. We review our allowances for doubtful accounts on a regular basis. We also consider whether the historical economic conditions are comparable to current economic conditions. If the financial condition of our customers or other parties that we have business relations with were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required.
	The balance of the receivables provision as at March 31, 2015 and December 31, 2014 was $19,084. The amount charged to bad debt provision for the three months ended March 31, 2015 and 2014 was $0 and $0, respectively.
Cash and cash equivalents	Cash and cash equivalents
	For purposes of the statements of cash flows, the Company considers all highly liquid instruments purchased with a maturity of three months or less and money market accounts to be cash equivalents. The Company maintains cash and cash equivalents with two financial institutions in the USA.
Revenue recognition	Revenue recognition
	Revenue sources consist of government grants, government contracts and commercial development contracts.
	We account for our long-term Firm Fixed Price Government contracts and grants associated with the delivery of research on drug candidates and the development of drug candidates using the percentage-of-completion accounting method. Under this method, revenue is recognized based on the extent of progress towards completion of the long-term contract.
	We generally use the cost-to-cost measure of progress for all of our long-term contracts, unless we believe another measure will produce a more reliable result. We believe that the cost-to-cost measure is the best and most reliable performance indicator of progress on our long-term contracts as all our contract estimates are based on costs that we expect to incur in performing our long-term contracts and we have not experienced any significant variations on estimated to actual costs to date. Under the cost-to-cost measure of progress, the extent of progress towards completion is based on the ratio of costs incurred-to-date to the total estimated costs at the completion of the long-term contract. Revenues, including estimated fees or profits are recorded as costs are incurred.
	When estimates of total costs to be incurred on a contract exceed total estimates of revenue to be earned, a provision for the entire loss on the contract is recorded in the period the loss is determined.
	To a much lesser extent, we enter into fixed fee commercial development contracts that are not associated with the delivery of feasible research on drug candidates and the development of drug candidates. Revenue under such contracts is generally recognized upon delivery or as the development is performed.
Sales and Marketing	Sales and Marketing
	Sales and marketing expenses are minimal at present. These costs, if any, are expensed as incurred and included in Selling, general and administrative expenses. The Company expects to incur sales and marketing expenses in future periods to promote its services to drug discovery enterprises.
Research and Development	Research and Development
	The remuneration of the Company’s research and development staff, materials used in internal research and development activities, and payments made to third parties in connection with collaborative research and development arrangements, are all expensed as incurred.  Where the Company makes a payment to a third party to acquire the right to use a product formula which has received regulatory approval, the payment is accounted for as the acquisition of a license or patent and is capitalized as an intangible asset and amortized over the shorter of the license period or the patent life.
	The amount expensed for unrecovered research costs, included in Selling, general and administrative expenses during the three months ended March 31, 2015 and 2014 was $75,034 and $72,403 respectively.
Patent Costs	Patent Costs
	Legal costs in connection with approved patents and patent applications are expensed as incurred and classified as Selling, general and administrative expense in our condensed consolidated statements of operations.
Share-Based Compensation	Share-Based Compensation
	Share-based compensation cost is measured at the grant date, based on the estimated fair value of the award and is recognized as expense over the employee's requisite service period or vesting period on a straight-line basis. Share-based compensation expense recognized in the condensed consolidated statements of operations for the three months ended March 31, 2015 and 2014 is based on awards ultimately expected to vest and has been reduced for estimated forfeitures. This estimate will be revised in subsequent periods if actual forfeitures differ from those estimates. We have no awards with market or performance conditions.
Income Taxes	Income Taxes
	The Company utilizes ASC 740, Accounting for Income Taxes, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
Net income (loss) per Share	Net income (loss) per Share
	Basic net income (loss) per share is computed on the basis of the weighted average number of common stock outstanding during the period.
	Diluted net income (loss) per share is computed on the basis of the weighted average number of common stock and common stock equivalents outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation.
	Dilution is computed by applying the treasury stock method for options and warrants. Under this method, “in-the money” options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
	Dilution is computed by applying the if-converted method for convertible preferred stocks. Under this method, convertible preferred stock is assumed to be converted at the beginning of the period (or at the time of issuance, if later), and preferred dividends (if any) will be added back to determine income applicable to common stock. The shares issuable upon conversion will be added to weighted average number of common stock outstanding. Conversion will be assumed only if it reduces earnings per share (or increases loss per share).
Related parties	Related parties
	Parties are considered to be related to the Company if the parties that, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. The Company shall disclose all related party transactions. All transactions shall be recorded at fair value of the goods or services exchanged. Property purchased from a related party is recorded at the cost to the related party and any payment to or on behalf of the related party in excess of the cost is reflected as a distribution to the related party.
Derivative Liabilities	Derivative Liabilities
	ASC 815 generally provides three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument subject to the requirements of ASC 815. ASC 815 also provides an exception to this rule when the host instrument is deemed to be conventional, as described.
	The Company had no derivative liabilities as of March 31, 2015.
Convertible Instruments	Convertible Instruments
	The Company evaluates and accounts for conversion options embedded in its convertible instruments in accordance with professional standards for “Accounting for Derivative Instruments and Hedging Activities”.
	Professional standards generally provide three criteria that, if met, require companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments. These three criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Professional standards also provide an exception to this rule when the host instrument is deemed to be conventional as defined under professional standards as “The Meaning of “Conventional Convertible Debt Instrument”.
	The Company accounts for convertible instruments (when it has determined that the embedded conversion options should not be bifurcated from their host instruments) in accordance with professional standards when “Accounting for Convertible Securities with Beneficial Conversion Features,” as those professional standards pertain to “Certain Convertible Instruments.” Accordingly, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their earliest date of redemption. The Company also records when necessary deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note.
	ASC 815-40 provides that, among other things, generally, if an event is not within the entity’s control could or require net cash settlement, then the contract shall be classified as an asset or a liability.
Recent accounting pronouncements	Recent accounting pronouncements
	In January 2015, the FASB issued ASU No. 2015-01, “Income Statement - Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” This ASU eliminates from U.S. GAAP the concept of extraordinary items. ASU 2015-01 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. We do not expect the adoption of ASU 2015-01 to have a material effect on our financial position, results of operations or cash flows.
	In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The ASU focuses on the consolidation evaluation for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. In addition to reducing the number of consolidation models from four to two, the new standard simplifies the FASB Accounting Standards Codification and improves current U.S. GAAP by placing more emphasis on risk of loss when determining a controlling financial interest, reducing the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity (“VIE”), and changing consolidation conclusions for companies in several industries that typically make use of limited partnerships or VIEs. The ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not expect the adoption of ASU 2015-02 to have a material effect on our financial position, results of operations or cash flows.
	In April 2015, FASB issued Accounting Standards Update (“ASU”) No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, is to simplify presentation of debt issuance costs by requiring that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The ASU does not affect the recognition and measurement guidance for debt issuance costs. For public companies, the ASU is effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early application is permitted. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.
	In April 2015, FASB issued Accounting Standards Update No. 2015-04, Compensation – Retirement Benefits (Topic 715): Practical Expedient for the Measurement Date of an Employer’s Defined Benefit Obligation and Plan Assets, permits the entity to measure defined benefit plan assets and obligations using the month-end that is closest to the entity’s fiscal year-end and apply that practical expedient consistently from year to year. The ASU is effective for public business entities for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Early application is permitted. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.
	In April 2015, FASB issued Accounting Standards Update No. 2015-05, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees paid in a Cloud Computing Arrangement, provides guidance to customers about whether a cloud computing arrangement includes a software license. If such an arrangement includes a software license, then the customer should account for the software license element of the arrangement consistent with the acquisition of other software licenses. If the arrangement does not include a software license, the customer should account for it as a service contract. For public business entities, the ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015. Early application is permitted. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.
	In April 2015, FASB issued Accounting Standards Update No. 2015-06, Earnings Per Share (Topic 260): Effects on Historical Earnings per Unit of Master Limited Partnership Dropdown Transactions, specifies that, for purposes of calculating historical earnings per unit under the two-class method, the earnings (losses) of a transferred business before the date of a drop down transaction should be allocated entirely to the general partner. In that circumstance, the previously reported earnings per unit of the limited partners (which is typically the earnings per unit measure presented in the financial statements) would not change as a result of the dropdown transaction. Qualitative disclosures about how the rights to the earnings (losses) differ before and after the dropdown transaction occurs for purposes of computing earnings per unit under the two-class method also are required. The ASU is effective for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. Earlier application is permitted. This updated guidance is not expected to have a material impact on our results of operations, cash flows or financial condition.
	Any new accounting standards, not disclosed above, that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the financial statements upon adoption.

Accounting_Policies_and_Estima2

Accounting Policies and Estimates (Tables)	3 Months Ended
	Mar. 31, 2015
Accounting Policies and Estimates [Abstract]
Summary of estimated useful lives of assets
	Leasehold improvements		5 Years
	Laboratory equipment		7 Years
	Furniture and fixtures		10 Years
	Computer equipment		3 Years
Summary of revenues by major customer type		Three months ended		Three months ended
		March 31,		March 31,
		2015		2014
	National Institutes of Health	$	30,653	$	254,220
		$	30,653	$	254,220

Intangible_Assets_Tables

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Intangible Assets [Abstract]
Summary of licenses cost		March 31,			December 31,
		2015			2014
		(unaudited)
	Patents and Licenses, at cost	$	972,000		$	972,000
	Less: Accumulated amortization		(493,714	)		(480,793	)
		$	478,286		$	491,207
Summary of amortization expense for future years		Amount
	Remainder of 2015	$	38,763
	2016		51,684
	2017		51,684
	2018		51,684
	2019 and thereafter		284,471
	Total	$	478,286

Plant_and_Equipment_Tables

Plant and Equipment (Tables)	3 Months Ended
	Mar. 31, 2015
Plant and Equipment [Abstract]
Components of Plant and equipment		March 31,			December 31,
		2015			2014
		(unaudited)
	Leasehold improvements	$	6,393		$	6,393
	Furniture and fittings		26,148			26,148
	Laboratory equipment		1,011,013			965,811
	Computer equipment		38,236			32,459
	Total		1,081,790			1,030,811
	Accumulated depreciation		(581,216	)		(549,160	)
		$	500,574		$	481,651

Other_Payables_and_Accrued_Exp1

Other Payables and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2015
Other Payables and Accrued Expenses [Abstract]
Schedule of other payables and accrued expenses
		March 31,		December 31,
		2015		2014
		(unaudited)
	Credit card liabilities	$	4,018	$	10,393
	Vacation and Sick Pay accrual		133,210		125,394
	Other payables		490,625		490,625
	Payroll liabilities		98,514		66,731
	Other		78,731		92,110
		$	805,098	$	785,253

Loans_Payable_Tables

Loans Payable (Tables)	3 Months Ended
	Mar. 31, 2015
Loans Payable [Abstract]
Schedule of loans payable
		March 31,		December 31,
		2015		2014
		(unaudited)
	Short term portion
	Los Alamos County project participation loan	$	34,985	$	34,552
	Long term portion
	Los Alamos County project participation loan		133,591		142,502
	Total	$	168,576	$	177,054
Schedule of amortization of principal outstanding of loans payable
		Amount
	Within 1 year	$	34,985
	1 to 2 years		36,775
	2 to 3 years		38,657
	3 to 4 years		40,634
	Thereafter		17,525
	Total	$	168,576

Warrants_Tables

Warrants (Tables)	3 Months Ended
	Mar. 31, 2015
Warrants [Abstract]
Summary of fair value assumptions of warrant			Three months
			ended  March 31,
			2015
	Calculated stock price		$	3.5
	Risk-free interest rate			2.12	%
	Expected life of options			5 Years
	Expected volatility of the underlying stock			119.3	%
	Expected dividend rate			0	%
Shedule of warrants outstanding and exercisable					Warrants Outstanding						Warrants Exercisable
	Exercise Price				Number of		Weighted average remaining		Weighted		Number of		Weighted
					shares		contractual		Average		Shares		Average
							years		Exercise Price				exercise Price
	$	3.5				1,653,865		4.62				1,653,865
	$	4				7,500		1.59				7,500
	$	4.2				150,000		2.86				150,000
	$	3.85				143,401		1				143,401
	$	11.4				192,204		1.19				192,204
						2,146,970		3.94	$	4.28		2,146,970	$	4.28

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Stock Based Compensation [Abstract]
Summary of weighted average assumptions			Three months ended
			March 31,
			2015
	Calculated stock price		$	3.50 – 4.00
	Risk-free interest rate			1.68% to 2.10	%
	Expected life of options			1- 10 Years
	Expected volatility of the underlying stock			119.3	%
	Expected dividend rate			0	%
Summary of changes stock option activity			Shares				Exercise				Weighted
							Price per				Average
							Share				Exercise Price
	Outstanding January 1, 2014			825,214			$	0.40  - 11.42			$	4.62
	Granted			156,000				5				5
	Forfeited/Cancelled			(255,262	)			5.00 - 11.42				5.26
	Exercised			-				-				-
	Outstanding December 31, 2014			725,952			$	0.40  - 11.42			$	3.82
	Granted			255,000				3.5				3.5
	Forfeited/Cancelled			-				-				-
	Exercised			-				-				-
	Outstanding March 31, 2015			980,952			$	0.40 - 11.42			$	3.82
Summary of information about stock options outstanding					Options Outstanding										Options Exercisable
	Exercise Price				Number of				Weighted average				Weighted		Number of		Weighted
					shares				remaining				Average		Shares		Average
									contractual years				Exercise Price				exercise Price
	$	0.4				15,000				7.09						15,000
	$	2.2				110,000				5.92						110,000
	$	3				312,500				7.96						312,500
	$	3.5				255,000				9.78						-
	$	4				64,270				3.26						63,020
	$	5				178,500				6.68						75,801
	$	11.42				45,682				3.91						45,682
						980,952				7.46			$	3.82		622,003	$	3.76

Net_Income_Loss_Per_Common_Sha1

Net Income (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2015
Net Income (Loss) Per Common Share [Abstract]
Summary of dilutive shares exercise of outstanding stock instruments		Three months ended
		March 31,
		2015
		(Shares)
	Options to purchase shares of common stock		980,952
	Warrants		2,146,970
	Series A convertible, redeemable preferred stock		105,000
			3,232,922
Computation of basic and diluted earnings per share		For the three months ended
		31-Mar-14
		Income			Shares		Per share amount
	Net income	$	5,420,979
	Preferred stock dividends		(149,993	)
	Basic Earnings per share
	Income available to common stockholders		5,270,986			2,076,760	$	2.54
	Effect of dilutive securities
	Warrants		-			19,823
	Options		-			14,973
	Series A Preferred stock		11,910			52,500
	Series B Preferred stock		138,083			1,066,974
	Diluted Earnings per share
	Income available to common stockholders and assumed conversions	$	5,420,979			3,231,030	$	1.68

Operating_Leases_Tables

Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2015
Operating Leases [Abstract]
Summary of future annual minimum payments required under operating lease obligations		Amount
	2015	$	168,068

Accounting_Policies_and_Estima3

Accounting Policies and Estimates (Details)	3 Months Ended
	Mar. 31, 2015
Leasehold improvements [Member]
Summary of estimated useful life of assets
Estimated useful lives of assets	5 years
Laboratory equipment [Member]
Summary of estimated useful life of assets
Estimated useful lives of assets	7 years
Furniture and fixtures [Member]
Summary of estimated useful life of assets
Estimated useful lives of assets	10 years
Computer equipment [Member]
Summary of estimated useful life of assets
Estimated useful lives of assets	3 years

Accounting_Policies_and_Estima4

Accounting Policies and Estimates (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Summary of revenues by major customer type
Total revenues	$30,653	$254,220
National Institutes of Health [Member]
Summary of revenues by major customer type
Total revenues	$30,653	$254,220

Accounting_Policies_and_Estima5

Accounting Policies and Estimates (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
	Segment
	Agency
Accounting Policies and Estimates (Textual)
Balance of bad debt provision	$19,084		$19,084
Amount credited to bad debt provision	0	0
Selling, general and administrative expenses	$75,034	$72,403
Number of reportable segments	1
Estimated useful life of license agreement	20 years
Number of government agencies involve in research contracts	2
Number of financial institutions to maintain cash deposit	2

Liquidity_Details

Liquidity (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Liquidity [Abstract]
Gross proceeds from private placement offering	$8,855,000

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Summary of licenses cost
Patents and Licenses, at cost	$972,000	$972,000
Less: Accumulated amortization	-493,714	-480,793
Total	$478,286	$491,207

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Summary of amortization expense for future years
2015	$38,763
2016	51,684
2017	51,684
2018	51,684
2019 and thereafter	284,471
Total	$478,286	$491,207

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Intangible Assets (Textual)
Amortization expense	$12,921	$12,920

Plant_and_Equipment_Details

Plant and Equipment (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Components of Plant and equipment
Total	$1,081,790	$1,030,811
Accumulated depreciation	-581,216	-549,160
Plant and equipment, net	500,574	481,651
Leasehold improvements [Member]
Components of Plant and equipment
Total	6,393	6,393
Furniture and fittings [Member]
Components of Plant and equipment
Total	26,148	26,148
Laboratory equipment [Member]
Components of Plant and equipment
Total	1,011,013	965,811
Computer equipment [Member]
Components of Plant and equipment
Total	$38,236	$32,459

Plant_and_Equipment_Details_Te

Plant and Equipment (Details Textual) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Plant and Equipment (Textual)
Depreciation	$32,226	$26,959

Other_Payables_and_Accrued_Exp2

Other Payables and Accrued Expenses (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Summary of other payables and accrued expenses
Credit card liabilities	$4,018	$10,393
Vacation and Sick Pay accrual	133,210	125,394
Other payables	490,625	490,625
Payroll liabilities	98,514	66,731
Other	78,731	92,110
Other payables and accrued expenses, current	$805,098	$785,253

Loans_Payable_Details

Loans Payable (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Schedule of loans payable
Short term portion	$34,985	$34,552
Long term portion	133,591	142,502
Total	168,576	177,054
Los Alamos County project participation loan [Member]
Schedule of loans payable
Short term portion	34,985	34,552
Long term portion	$133,591	$142,502

Loans_Payable_Details_1

Loans Payable (Details 1) (USD $)	Mar. 31, 2015	Dec. 31, 2014
Schedule of amortization of principal outstanding on loans payable
Within 1 year	$34,985
1 to 2 years	36,775
2 to 3 years	38,657
3 to 4 years	40,634
Thereafter	17,525
Total	$168,576	$177,054

Loans_Payable_Details_Textual

Loans Payable (Details Textual) (USD $)	0 Months Ended	3 Months Ended	12 Months Ended
	Sep. 21, 2006	Mar. 31, 2015	Dec. 31, 2007	Dec. 31, 2014
Loans Payable (Textual)
Amount owed by company		$168,576		$177,054
Los Alamos County Loan [Member]
Loans Payable (Textual)
Maximum funding, loan amount	2,200,000
Term of loan	13 years
Maximum funding loan amount for equipment	625,000
Payment term of loan		No repayments for 36 months with 120 equal monthly repayments commencing on September 21, 2009.
Interest rate on loan	5.00%
Value of purchased assets			302,009
Equal monthly repayments, amount	3,547
Amount owed by company		$168,576		$177,054

Preferred_Stock_Details

Preferred Stock (Details) (USD $)	3 Months Ended		0 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Apr. 30, 2013	Jan. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Preferred Stock (Textual)
Preferred stock, par value	$0.00
Preferred stock, shares designated	10,000,000				10,000,000
Number of preferred stock shares undesignated	6,600,000
Preferred stock, dividend rate - Series A	8.00%
Convertible redeemable preferred stock, description	400,000 are designated as Series A 8% convertible redeemable preferred shares of $0.001 each
Minimum litigation proceedings, net	$3,000,000
Preferred Stock, redeemable option, description	Redeem the Series A Stock at a price equal to 130% of the initial investment in the Company by the stockholder at any time after giving the investors notice and allowing them to exercise their conversion rights into common stock 30 days after notice has been received.
Liquidation rights of preferred stock, per share - Series A					$5.70
Preferred stock dividend rate - Series B	Series B Stock accrue dividends at the rate per annum equal to (i) 8% of the sum of (x) the Stated Value and (y) the amount of accrued and unpaid dividends payable, out of funds legally available for payment, on January 31st of each year, if paid in cash, or (ii) 10% of the sum of (x) the Stated Value and (y) the amount of accrued and unpaid dividends payable, out of funds legally available for payment, on January 31st of each year, if paid in shares of Common Stock, based upon a price of $5.00 per share of Common Stock. The Company shall have the option, to pay any such dividends in cash or shares of Common Stock. Such dividends shall be in preference and priority to any payment of any dividend on Common Stock, or any other class of preferred stock.
Weighted average price of common stock, Minimum per share	$10
Warrant expiration period - Series A	5 years
Minimum purchase price of common stock	$2.50
Maximum common stock under equity incentive plans	1,000,000
Series B convertible preferred stock voting rights, Description	Each holder of Series B Stock is entitled to cast the number of votes equal to two times the number of shares of Common Stock into which such shares of Series B Stock could be converted at the record date for determining stockholders entitled to vote at the meeting.
Common stock, par value	$0.00				$0.00
Series A dividends paid in cash	-48,300
Series A convertible redeemable preferred shares [Member]
Preferred Stock (Textual)
Preferred stock, par value	$0.00				$0.00
Preferred stock, shares designated	400,000				400,000
Preferred stock, shares issued	105,000				105,000
Preferred stock, shares outstanding	105,000				105,000
Convertible preferred stock terms of conversion, Conversion price	11.4		11.4
Share price	$20
Convertible Preferred Stock Exchanged			170,804
Liquidation rights of preferred stock, per share - Series A	$5.70
Series B convertible preferred stock [Member]
Preferred Stock (Textual)
Preferred stock, par value	$0.00				$0.00	$0.00
Convertible redeemable preferred stock, shares designated	3,000,000				3,000,000
Preferred stock, shares issued	0				2,133,947	2,133,947
Preferred stock, shares outstanding	0			2,133,947	2,133,947	2,133,947
Accrual preferred stock dividends	48,745	138,083
Common stock, par value				$0.00
Preferred stock, dividend per share				$3.50
Preferred stock converted to common stock				1,803,820
Series A Preferred Stock [Member]
Preferred Stock (Textual)
Convertible redeemable preferred stock, shares designated	400,000				400,000
Investment from Stockholder	210,000
Carrying value series A stock	133,350
Accrual preferred stock dividends	$11,910	$11,910

Common_Stock_Details

Common Stock (Details) (USD $)	0 Months Ended		12 Months Ended	1 Months Ended	3 Months Ended	1 Months Ended
	Mar. 04, 2015	Jan. 07, 2015	Dec. 31, 2014	Dec. 31, 2014	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2013
Common Stock (Textual)
Common stock, shares authorized			50,000,000	50,000,000	50,000,000
Common stock, par value			$0.00	$0.00	$0.00
Common stock, shares issued			3,780,847	3,780,847	6,700,707
Common stock, shares outstanding			3,453,847	3,453,847	6,373,707
Private placement offering [Member]
Common Stock (Textual)
Common stock, shares issued			2,530,000	2,530,000	632,531
Sale of stock	20,000	1,265,000
Price per share	$0.02		$7	$7
Sale of stock, cash received	$400	$8,855,000	$5,018,867
Sale of stock, description			Private placement offering (the "Offering") 716,981 units at a per unit price of $7.00, each unit (the "Units") consisting of four shares of common stock of the Company (the "Shares")
Private placement offering [Member] | Purchase Agreement [Member]
Common Stock (Textual)
Sale of stock		548,019
Term of warrants		5 years
Sale of stock, cash received		3,836,133
Exclusive Placement Offering [Member]
Common Stock (Textual)
Gross proceeds offering					708,400
Own Share Leading Arrangement Reimbursed					35,000
Share issue expenses to common stock		$753,551		$753,551
Arrangement of placement description					In connection therewith, the Company agreed to pay the placement agent an eight percent (8%)
Series B convertible preferred stock [Member]
Common Stock (Textual)
Common stock, par value						$0.00
Preferred stock, dividend per share						$3.50
Preferred stock converted to common stock						1,803,820
Preferred stock, shares outstanding			2,133,947	2,133,947	0	2,133,947	2,133,947

Warrants_Details

Warrants (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Warrants [Abstract]
Calculated stock price	$3.50
Risk-free interest rate	2.12%
Expected life of options	5 years
Expected volatility of the underlying stock	119.30%
Expected dividend rate	0.00%

Warrants_Details_1

Warrants (Details 1) (Warrant [Member], USD $)	3 Months Ended
	Mar. 31, 2015
Outstanding And Exercisable Warrants [Abstract]
Number of shares, warrants outstanding	2,146,970
Weighted average remaining contractual years, warrants outstanding	3 years 11 months 9 days
Weighted average exercise price, warrants outstanding	$4.28
Number of shares, warrants exercisable	2,146,970
Weighted average exercise price, warrants exercisable	$4.28
Three Point Five Zero [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$3.50
Number of shares, warrants outstanding	1,653,865
Weighted average remaining contractual years, warrants outstanding	4 years 7 months 13 days
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	1,653,865
Weighted average exercise price, warrants exercisable
Four [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$4
Number of shares, warrants outstanding	7,500
Weighted average remaining contractual years, warrants outstanding	1 year 7 months 2 days
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	7,500
Weighted average exercise price, warrants exercisable
Four Point Two Zero [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$4.20
Number of shares, warrants outstanding	150,000
Weighted average remaining contractual years, warrants outstanding	2 years 10 months 10 days
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	150,000
Weighted average exercise price, warrants exercisable
Three Point Eight Five [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$3.85
Number of shares, warrants outstanding	143,401
Weighted average remaining contractual years, warrants outstanding	1 year
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	143,401
Weighted average exercise price, warrants exercisable
Eleven Point Four Zero [Member]
Outstanding And Exercisable Warrants [Abstract]
Exercise price	$11.40
Number of shares, warrants outstanding	192,204
Weighted average remaining contractual years, warrants outstanding	1 year 2 months 9 days
Weighted average exercise price, warrants outstanding
Number of shares, warrants exercisable	192,204
Weighted average exercise price, warrants exercisable

Warrants_Details_Textual

Warrants (Details Textual) (USD $)	3 Months Ended		0 Months Ended		1 Months Ended	12 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 04, 2015	Jan. 07, 2015	Jan. 31, 2015	Dec. 31, 2014
Warrants Textual [Abstract]
Stock based compensation charge	$209,862	$186,523
BluePrint Media, LLC [Member]
Warrants Textual [Abstract]
Exercise Price	$3.50
Warrants issued to purchase common stock	32,500
Stock based compensation charge	94,095
Private Placement [Member]
Warrants Textual [Abstract]
Exercise price of warrants					3.85
Sale of stock			20,000	1,265,000
Price per share			$0.02			$7
Sale of stock, cash received			$400	$8,855,000		$5,018,867
Private Placement [Member] | Agent Fees [Member]
Warrants Textual [Abstract]
Warrants issued to purchase common stock					143,401
Bridge Warrant Holders [Member] | Existing Series B Warrants (Member)
Warrants Textual [Abstract]
Warrants issued to purchase common stock					150,000
Exercise price of warrants					4.2
Placement Agent [Member] | Bridge Loan [Member]
Warrants Textual [Abstract]
Percentage of warrants exercise price					30.00%
Placement Agent [Member] | Existing Series B Warrants (Member)
Warrants Textual [Abstract]
Warrants issued to exchange of series B preferred stock and common stock					635,834
Exercise price of warrants					3.5
Five Year Warrants [Member] | Placement Agent [Member]
Warrants Textual [Abstract]
Exercise Price				$3.50
Warrants issued to purchase common stock				253,000
Exercise price of warrants				1.75
Additional warrants for purchase of common stock				100,000
Sale of offering cost				548,019

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Summary of weighted average assumptions
Risk-free interest rate, Minimum	1.68%
Risk-free interest rate, Maximum	2.10%
Expected life of options	5 years
Expected volatility of the underlying stock	119.30%
Expected dividend rate	0.00%
Maximum [Member]
Summary of weighted average assumptions
Calculated stock price	4
Expected life of options	10 years
Minimum [Member]
Summary of weighted average assumptions
Calculated stock price	3.5
Expected life of options	1 year

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (Stock Options [Member], USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2015	Dec. 31, 2014
Summary of changes in options outstanding
Shares Outstanding, Beginning balance	725,952	825,214
Shares, Granted	255,000	156,000
Shares, Forfeited/Cancelled	0	-255,262
Shares, Exercised
Shares Outstanding, Ending balance	980,952	725,952
Exercise price per share, Granted	$3.50	$5
Exercise price per share Forfeited/Cancelled
Exercise price per share, Exercised
Weighted Average Exercise Price, Beginning Balance	$3.82	$4.62
Weighted Average Exercise Price, Granted	$3.50	$5
Weighted Average Exercise Price, Forfeited/Cancelled		$5.26
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Ending Balance	$3.82	$3.82
Minimum [Member]
Summary of changes in options outstanding
Exercise price per share, Beginning balance		$0.40
Exercise price per share Forfeited/Cancelled		$5
Exercise price per share, Ending balance	$0.40	$0.40
Maximum [Member]
Summary of changes in options outstanding
Exercise price per share, Beginning balance		$11.42
Exercise price per share Forfeited/Cancelled		$11.42
Exercise price per share, Ending balance	$11.42	$11.42

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details 2) (Stock Options [Member], USD $)	3 Months Ended
	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Summary of information about stock options outstanding
Number of shares, Options Outstanding	980,952	725,952	825,214
Weighted average remaining contractual years, Option outstanding	7 years 5 months 16 days
Weighted Average Exercise Price, Option Outstanding	$3.82	$3.82	$4.62
Number of Shares, Option exercisable	622,003
Weighted Average exercise Price, Options Exercisable	$3.76
0.40 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$0.40
Number of shares, Options Outstanding	15,000
Weighted average remaining contractual years, Option outstanding	7 years 1 month 2 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	15,000
Weighted Average exercise Price, Options Exercisable
2.20 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$2.20
Number of shares, Options Outstanding	110,000
Weighted average remaining contractual years, Option outstanding	5 years 11 months 1 day
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	110,000
Weighted Average exercise Price, Options Exercisable
3.00 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$3	$1.50
Number of shares, Options Outstanding	312,500	625,000
Weighted average remaining contractual years, Option outstanding	7 years 11 months 16 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	312,500
Weighted Average exercise Price, Options Exercisable
3.50 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$3.50	$1.50
Number of shares, Options Outstanding	255,000	625,000
Weighted average remaining contractual years, Option outstanding	9 years 9 months 11 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable
Weighted Average exercise Price, Options Exercisable
4.00 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$4
Number of shares, Options Outstanding	64,270
Weighted average remaining contractual years, Option outstanding	3 years 3 months 4 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	63,020
Weighted Average exercise Price, Options Exercisable
5.00 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$5
Number of shares, Options Outstanding	178,500
Weighted average remaining contractual years, Option outstanding	6 years 8 months 5 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	75,801
Weighted Average exercise Price, Options Exercisable
11.42 [Member]
Summary of information about stock options outstanding
Exercise Price, Options Outstanding	$11.42	$1.50
Number of shares, Options Outstanding	45,682	625,000
Weighted average remaining contractual years, Option outstanding	3 years 10 months 28 days
Weighted Average Exercise Price, Option Outstanding
Number of Shares, Option exercisable	45,682
Weighted Average exercise Price, Options Exercisable

Stock_Based_Compensation_Detai3

Stock Based Compensation (Details Textual) (USD $)	1 Months Ended	3 Months Ended		12 Months Ended	0 Months Ended
	Oct. 31, 2005	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Feb. 03, 2015	Mar. 12, 2015	Jan. 07, 2015	Feb. 02, 2015
Stock Based Compensation (Textual)
Shares of common stock for issuance upon exercise of grants under plan	1,500,000
Share-based payment award, award vesting period			Either immediately or over a period of up to two years, and expire 1 year to 10 years from the grant date.
Shares available for future grant under the Incentive Plan		519,048
Stock option based compensation expense		$209,862	$186,523
Share based payment award minimum expiry period	1 year
Share based payment award maximum expiry period	10 years
Short term maturities period	3 months
Expected dividend yield		0.00%
Stock options outstanding intrinsic value		345,750		345,750
Weighted-average grant-date fair values of options granted		844,577		302,080
Weighted-average grant-date fair values of options granted per share		$3.31		$1.94
Unvested options to purchase common stock		358,949
Expected unrecognized compensation cost		989,391
Expected to be recognized over period				46 months
Number of options expected to vest in future								1,250
Stock Options [Member]
Stock Based Compensation (Textual)
Options exercisable cancelled		0		255,262
Weighted-average grant-date fair values of options granted per share					$3.50
Stock options exercised
Number of options expected to vest in future								5,000
Stock options vesting period					10 years
Board of directors [Member]
Stock Based Compensation (Textual)
Shares of common stock for issuance upon exercise of grants under plan		56,770
Stock option based compensation expense						$32,375
Weighted-average grant-date fair values of options granted per share						$11.40
Share-based compensation arrangement by share-based payment award, Description						Exercisable at priced of $11.40 per share which exercise price has been reduced to $4.00 per share.
CEO [Member]
Stock Based Compensation (Textual)
Weighted-average grant-date fair values of options granted per share							$3.50
Stock options exercised							250,000
Stock options vesting period							10 years
CEO [Member] | November 24, 2015 one [Member]
Stock Based Compensation (Textual)
Number of options expected to vest in future							50,000
CEO [Member] | November 24, 2015 two [Member]
Stock Based Compensation (Textual)
Number of options expected to vest in future							150,000
CEO [Member] | November 24, 2018 [Member]
Stock Based Compensation (Textual)
Number of options expected to vest in future							50,000

Net_Income_Loss_Per_Common_Sha2

Net Income (Loss) Per Common Share (Details)	3 Months Ended
	Mar. 31, 2015
Summary of dilutive shares exercise of outstanding stock instruments
Anti Dilutive shares pursuant to the exercise of outstanding stock instruments	3,232,922
Options to purchase shares of common stock [Member]
Summary of dilutive shares exercise of outstanding stock instruments
Anti Dilutive shares pursuant to the exercise of outstanding stock instruments	980,952
Warrants [Member]
Summary of dilutive shares exercise of outstanding stock instruments
Anti Dilutive shares pursuant to the exercise of outstanding stock instruments	2,146,970
Series A convertible, redeemable preferred stock [Member]
Summary of dilutive shares exercise of outstanding stock instruments
Anti Dilutive shares pursuant to the exercise of outstanding stock instruments	105,000

Net_Income_Loss_Per_Common_Sha3

Net Income (Loss) Per Common Share (Details 1) (USD $)	3 Months Ended
	Mar. 31, 2015		Mar. 31, 2014
Earnings Per Share, Basic and Diluted [Abstract]
Net (loss) income	($1,427,918)		$5,420,979
Preferred stock dividends	-60,655		-149,993
Basic Earnings per share
Income available to common stockholders	-1,488,573		5,270,986
Income available to common stockholders, shares	5,653,144	[1]	2,076,760	[1]
Income available to common stockholders, per share	($0.26)		$2.54
Effect of dilutive securities
Warrants
Warrants, shares			19,823
Options
Options, shares			14,973
Series A Preferred stock	11,910		11,910
Series A Preferred stock, shares			52,500
Series B Preferred stock	48,745		138,084
Series B Preferred stock, shares			1,066,974
Diluted Earnings per share
Income available to common stockholders and assumed conversions			$5,420,979
Income available to common stockholders and assumed conversions, shares	5,653,144	[1]	3,231,030	[1]
Income available to common stockholders and assumed conversions, per share	($0.26)		$1.68
[1]	After giving retrospective effect to a 2 for 1 reverse stock split which became effective on March 25, 2015 after filing a certificate of amendment to the certificate of incorporation.

Net_Income_Loss_Per_Common_Sha4

Net Income (Loss) Per Common Share (Details Textual)	3 Months Ended
	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,232,922
Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	699,902
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,128,935

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	0 Months Ended
	Jan. 07, 2015	Mar. 31, 2015	Dec. 31, 2014
Related Party Transactions (Textuals)
Majority of common shares owned by Dr. Benjamin Warner		27.00%	46.20%
Mr. Richard Cunningham [Member]
Related Party Transactions (Textuals)
Options granted	250,000
Exercise price	$3.50
Share based payment award description	(i) Fifty Thousand (50,000) shares shall vest on November 24, 2015; (ii) One Hundred and Fifty Thousand (150,000) shares shall vest monthly on a pro rata basis commencing on December 31, 2015 for a period of forty eight months; and (iii) Fifty Thousand (50,000) shares shall vest on the November 24, 2018.

Operating_Leases_Details

Operating Leases (Details) (USD $)	Mar. 31, 2015
Summary of future annual minimum payments required under operating lease obligations
2015	$168,068

Operating_Leases_Details_Textu

Operating Leases (Details Textual) (USD $)	0 Months Ended	3 Months Ended
	Oct. 10, 2014	Mar. 31, 2015
Laboratory and office lease [Member]
Operating Leases (Textual)
Area of leased office space (in square feet)		2,813
Term of lease		18 months
Lease expiration date		31-Dec-15
Monthly rent expense under lease agreement		$16,600
Rental expense		47,798
New Corporate Apartment Lease [Member]
Operating Leases (Textual)
Term of lease		1 year
Lease expiration date		1-Jun-14
Monthly rent expense under lease agreement		2,500
Rental expense		7,500
Office lease [Member]
Operating Leases (Textual)
Lease expiration date		31-Oct-13
Monthly rent expense under lease agreement		5,075
Rental expense		15,226
Third Corporate Apartment Lease [Member]
Operating Leases (Textual)
Term of lease	9 months
Lease expiration date	6-Jul-15
Monthly rent expense under lease agreement	3,351
Rental expense		$10,205

Litigation_Details

Litigation (Details) (USD $)	3 Months Ended	0 Months Ended
	Mar. 31, 2015	Aug. 25, 2014	Apr. 14, 2015
Peter Schmiedel [Member]
Litigation (Textual)
Attorneys' fees and costs	$37,080
Redemption Litigation [Member]
Litigation (Textual)
Series A Preferred stock, Dividends per share		$7.41
American Millings [Member]
Litigation (Textual)
Attorneys' fees and costs	158,816.97
QTM Ventures, LLC [Member]
Litigation (Textual)
Attorneys' fees and costs	80,603.75
Subsequent Event [Member]
Litigation (Textual)
Term of litigation			(1) found that Sigmund Eisenschenk's rights in the Company's stock were not collected, recalled, or cancelled, (2) partially vacated the Michael T Lyon or the Michael T Lyon Profit Sharing Plan and Richard Lane's claims against the Estate, and (3) granted partial summary judgment against the Company and declared that the Estate of Eisenschenk owns no less than 177,500 shares of the Company's stock (which number of shares is prior to the reverse split, and will amount to 88,750 shares post the reverse split which took place on March 25, 2015).
Shares of stock reverse split			177,500
Reverse stock split value			88,750
Subsequent Event [Member] | Sigmund Eisenschenk [Member]
Litigation (Textual)
Shares of stock reverse split			177,500
Reverse stock split value			$88,750